Compare Indonesia Energy Corporation Limited (INDO) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Sanofi SA — how do they compare? Indonesia Energy Corporation Limited trades at $2.79 (market cap $43.24M), while Sanofi SA trades at $40.16 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 2201.2× Indonesia Energy Corporation Limited's market cap, and Sanofi SA pays a 6.01% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and Sanofi SA for 94 Days on average.
| INDO | SNY | |
|---|---|---|
Market Cap | $43.24M | $95.18B |
Volume | 116,953 | 2,995,646 |
Sector | Energy | Health |
52-Week High | $6.74 | $52.34 |
52-Week Low | $2.49 | $39.51 |
Typical Hold Time | 24 Days | 94 Days |
Enterprise Value | $38.18M | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.79, up 0.72% on the day, amid a bearish technical signal. The company reported a net loss of $5.10M on $2.01M revenue for 2025, with negative profit margins. Recent news highlights operational progress, including oil discovery at the K-29 well and participation in investment conferences.
Despite unanimous analyst buy ratings, INDO faces significant financial challenges with persistent losses and negative cash flow from operations. The stock's outlook hinges on successful production scaling from new wells, but execution risks and weak fundamentals present substantial downside potential for investors.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
